Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

Université de Sherbrooke

$25,000.00

Procedure optimization for preparing human fecal samples for mass spectrometry analysis******

FY 2018-19

Summary
Biomarkers are defined as molecules (e.g. DNA, RNA, proteins) that indicate an alteration of the physiological condition of an individual in relation to health and disease. Stool samples offer a non-invasive and biologically relevant material for the search of biomarkers of intestinal diseases such as colorectal cancer (CRC) and the inflammatory bowel diseases (IBD). Despite a great potential for medical application, the research on human fecal protein biomarkers remains relatively narrow to this date. * Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers a potent approach for investigating the fecal proteome and characterizing biomarkers. However, the protein composition of feces is very complex and the development of a worthy protocol for the analysis of human stool proteins with this technology can be complicated. The objective of the project presented in this application is to establish a protocol that optimizes the efficacy and consistency of human protein detection by LC-MS/MS with the specific instrumentation of our partner - PhenoSwitch Bioscience Inc. The transfer of the protocol to this company will serve to increase their MS services and future business opportunities such as analyzing samples from healthy, CRC and IBD patients in order to identify biomarker candidates and to validate our LC-MS/MS strategy. * In the context where the health sciences and medicine are moving rapidly toward a more comprehensive use of biomarkers, this project will lay the foundation for the development of innovative MS-based tests that improve the screening and diagnosis of intestinal diseases. The future potential benefits of such innovation for Canada are multiple and encompass reducing the number of unnecessary colonoscopies and enhancing the survival rate of patients with CRC, both of which are desirable for Canadian patients and the health system. *
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
537631-2018
Name nom
Beaulieu, JeanFrançois
Department département
Anatomie et biologie cellulaire
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Procedure optimization for preparing human fecal samples for mass spectrometry analysis******
Keyword
NSERC
Application summary
Biomarkers are defined as molecules (e.g. DNA, RNA, proteins) that indicate an alteration of the physiological condition of an individual in relation to health and disease. Stool samples offer a non-invasive and biologically relevant material for the search of biomarkers of intestinal diseases such as colorectal cancer (CRC) and the inflammatory bowel diseases (IBD). Despite a great potential for medical application, the research on human fecal protein biomarkers remains relatively narrow to this date. * Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers a potent approach for investigating the fecal proteome and characterizing biomarkers. However, the protein composition of feces is very complex and the development of a worthy protocol for the analysis of human stool proteins with this technology can be complicated. The objective of the project presented in this application is to establish a protocol that optimizes the efficacy and consistency of human protein detection by LC-MS/MS with the specific instrumentation of our partner - PhenoSwitch Bioscience Inc. The transfer of the protocol to this company will serve to increase their MS services and future business opportunities such as analyzing samples from healthy, CRC and IBD patients in order to identify biomarker candidates and to validate our LC-MS/MS strategy. * In the context where the health sciences and medicine are moving rapidly toward a more comprehensive use of biomarkers, this project will lay the foundation for the development of innovative MS-based tests that improve the screening and diagnosis of intestinal diseases. The future potential benefits of such innovation for Canada are multiple and encompass reducing the number of unnecessary colonoscopies and enhancing the survival rate of patients with CRC, both of which are desirable for Canadian patients and the health system. *